Share
PrintCordStat
CordStat®
The current “best practices” procedure for diagnosing the in utero drug exposure of a fetus is testing the newborn’s meconium for the presence of drugs. Meconium is, however, difficult to collect. In up to 20 percent of live births, the meconium is released into the amniotic fluid pre-birth due to some type of fetal distress, drug and alcohol abuse often being one of these stress factors. While drugs may have induced this fetal distress, it is unlikely that these infants will be tested for drug exposure due to lack of available meconium for testing. The opportunity to provide these infants with appropriate treatment and intervention is lost.
CordStat® is a new drug test format that utilizes umbilical cord tissue as the sample matrix. CordStat® provides several advantages over the meconium testing matrix:
- Umbilical cord sections are easy to collect, store and ship.
- Umbilical cord sections are always available for testing.
- In many instances umbilical cord testing results will be available earlier (1-2 days) than meconium testing results.
- Studies have shown that umbilical cord sections demonstrate a greater sensitivity than meconium for the specific drugs methamphetamine and marijuana.
- Umbilical cord sections have a window of detection for abused drugs equal to or greater than that provided by meconium.
CordStatSM is available in 5-, 7-, 9-, 12- and 13-drug panels.
Drug Panels
5-drug panel: amphetamines, cannabinoids, cocaine, opiates, phencyclidine (PCP)
7-drug panel: 5-drugs plus methadone and barbiturates
9-drug panel: 7-drugs plus benzodiazepines and propoxyphene
12-drug panel: 9-drugs plus meperidine, tramadol and oxycodone
13-drug panel: 12-drugs plus buprenorphine
Click here to view a list of expanded drug panels
Collection instructions
Download collection instructions
Frequently Asked Questions